Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to further evaluate the PK characteristics of PF-04856883.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PF-04856883 Treatment Arm 1 | Experimental |
| |
| PF-04856883 Treatment Arm 2 | Experimental |
| |
| PF-04856883 Treatment Arm 3 | Experimental |
| |
| PF-04856883 Treatment Arm 4 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PF-04856883 | Biological | Dose A |
| |
| PF-04856883 |
| Measure | Description | Time Frame |
|---|---|---|
| PF-04856883 Pharmacokinetics including Cmax, Tmax, AUCo-infinity, AUClast, Cl/F, Vz/F and t1/2 | 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Number of subjects with AEs reported | 4 weeks | |
| Number of subjects with abnormal physical examination findings | 4 weeks | |
| Number of subjects with abnormal clinical laboratory results |
Not provided
Inclusion Criteria:
-
Exclusion Criteria:
-
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| New Haven Clinical Research Unit | New Haven | Connecticut | 06511 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Biological |
Dose B |
|
| PF-04856883 | Biological | Dose C |
|
| PF-04856883 | Biological | Dose D |
|
| 4 weeks |
| Number of subjects with abnormal ECGs | 4 weeks |
| Number of subjects with abnormal vital signs | 4 weeks |